Scandion Oncology AS (STU:8VY)
€ 0.0066 0.0004 (6.45%) Market Cap: 1.64 Mil Enterprise Value: -324,000.00 PE Ratio: 0 PB Ratio: 0.51 GF Score: 0/100

Q2 2022 Scandion Oncology A/S Earnings Call Transcript

Aug 25, 2022 / 08:00AM GMT
Release Date Price: €0.214882 (+2.08%)
Bo Rode Hansen;S;President;CEO
Scandion Oncology A

/-&

Thank you, and good morning, everyone. Welcome to our second-quarter 2022 interim report investor call. As you heard, my name is Bo Rode Hansen, and I'm the CEO and President of Scandion Oncology. And with me today is our Chief Financial Officer, Johnny Stilou. Johnny and I will be updating you on the developments and financial results for the second quarter of 2022, as well as recent events in the company.

We are very happy with our achievements in the quarter. First and foremost, raising capital to enhance our financial position. I'm also glad to report that we continue our strong operational execution and progress in our clinical trials. Following our presentation, Johnny and I are happy to take your questions.

Please be informed that in order to best address your questions, we ask you to state these verbally. It will not be possible to put questions forward in writing. So if you have a question, please follow the operator's instructions and ask verbally. Again, welcome, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot